FMP
Sep 23, 2024 8:00 PM - Alex Lavoie(Last modified: Sep 24, 2024 7:13 AM)
Image credit: Google Images
BrainsWay Ltd. (NASDAQ:BWAY) operates in the medical device industry, focusing on developing noninvasive treatments for mental health disorders. Its main product, Deep Transcranial Magnetic Stimulation technology, offers a novel approach to treating conditions such as major depressive disorders and smoking addiction. This positions BrainsWay in a unique niche within the healthcare sector, competing against both traditional pharmaceutical treatments and other medical device companies.
The company's financial metrics reveal a Weighted Average Cost of Capital (WACC) of 5.01% and a Return on Invested Capital (ROIC) of 1.33%. The ROIC/WACC ratio, a key indicator of financial performance and efficiency in generating returns on investment relative to the cost of capital, stands at 0.26 for BrainsWay. This suggests that while the company is generating returns above its cost of capital, the efficiency of these returns is relatively low compared to some of its peers.
In contrast, Axcella Health Inc. (NASDAQ:AXLA), a peer in the biotechnology sector, showcases an extraordinary ROIC/WACC ratio of 412.40. This indicates that Axcella Health is not only generating returns well above its cost of capital but doing so with remarkable efficiency. Such a high ratio points to significant growth potential and effective use of capital, making it an attractive option for investors looking for companies with strong value creation capabilities.
Other peers in the analysis, such as Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), Acutus Medical, Inc. (NASDAQ:AFIB), Neuronetics, Inc. (NASDAQ:STIM), and Apyx Medical Corporation (NASDAQ:APYX), show a wide range of ROIC/WACC ratios, from highly negative to moderately positive. This diversity highlights the varying degrees of financial health and efficiency in capital use within the sector, with some companies struggling to generate returns above their cost of capital.
Overall, the analysis of BrainsWay and its peers underscores the importance of the ROIC/WACC ratio as a measure of a company's ability to create value for its investors. While BrainsWay maintains a positive ratio, indicating it is generating returns above its cost of capital, the comparison with Axcella Health Inc. and other peers reveals significant differences in financial efficiency and growth potential within the industry.
May 14, 2024 11:41 AM - Sanzhi Kobzhan
A stock's target price, also known as its fair value, is an indication of what a share can cost based on the company’s forecasted financial statements. It is important to know a stock's fair value to find undervalued stocks with great growth potential. Let's consider how investment analysts calculat...
May 16, 2024 8:06 PM - Gordon Thompson
On Thursday, May 16, 2024, Deutsche Bank upgraded its rating on NASDAQ:ASTS to Buy, maintaining a hold position. At the time of the announcement, ASTS was trading at $4.03. This decision was accompanied by an increase in the price target for AST SpaceMobile, raised to $22 from $19, as detailed in a ...
May 24, 2024 9:30 AM - Rajnish Katharotiya
Earnings call transcripts are invaluable resources for investors, analysts, and financial enthusiasts. They provide insights into a company's performance, strategy, and future outlook, making them essential for making informed investment decisions. With Financial Modeling Prep, Earnings Call Transcr...